Abu Dhabi, UAE – 22 April 2025 – Abu Dhabi Health Data Services (ADHDS), part of M42’s Digital Health Solutions (DHS) platform, has announced a collaboration with Syndesis Health, one of the world’s largest holders of phenotype data, encompassing over 70 million patient profiles. The term sheet was signed by Kareem Shahin, CEO of M42’s Digital Health Solutions platform and Josh Sutton, CEO of Syndesis Health, reinforcing Abu Dhabi’s position as a global hub for digital health innovation.

This collaboration brings together Syndesis Health’s extensive phenotype database and ADHDS’s cutting-edge digital health infrastructure to drive advancements in AI-powered genomic analytics, precision medicine, and drug discovery. By combining real-world data with advanced artificial intelligence, the collaboration aims to accelerate innovation in clinical decision support and pharmaceutical research, ultimately improving treatment pathways for patients worldwide.

The partnership will focus on three key areas:

• Commercializing phenotype data to support global pharmaceutical, biotech, and academic research.
• Developing AI-driven predictive models that enable personalized and data-driven healthcare while maintaining strict compliance with international data governance standards.
• Enhancing genomic analytics to improve prescription safety and reduce adverse drug reactions through AI-powered pharmacogenomics.

By leveraging their complementary capabilities, the parties have signed a term sheet outlining their intent to establish a joint venture focused on generating valuable insights to accelerate drug development, enhance patient outcomes, and support the advancement of the healthcare infrastructure. This potential collaboration aligns with the Abu Dhabi’s vision of positioning itself as global leader in digital health and biomedical research.

Kareem Shahin, CEO of M42’s Digital Health Solutions platform, emphasized the significance of the partnership, stating: "This collaboration represents a major step forward in harnessing real-world data and AI to transform healthcare. By integrating Syndesis Health’s vast phenotype dataset with our digital health expertise, we are opening new frontiers in genomic analytics and drug discovery."

Josh Sutton, CEO of Syndesis Health, added: "The collaboration between Syndesis Health and ADHDS will generate groundbreaking insights that accelerate pharmaceutical innovation and improve patient outcomes. Together, we are setting new benchmarks for AI-driven healthcare solutions."

With a shared commitment to advancing global healthcare through data-driven innovation, this partnership marks a significant milestone in the evolution of precision medicine and AI-powered drug discovery.